EP2297341A4 - Methods and compositions for the treatment of huntington's disease - Google Patents
Methods and compositions for the treatment of huntington's diseaseInfo
- Publication number
- EP2297341A4 EP2297341A4 EP09741640A EP09741640A EP2297341A4 EP 2297341 A4 EP2297341 A4 EP 2297341A4 EP 09741640 A EP09741640 A EP 09741640A EP 09741640 A EP09741640 A EP 09741640A EP 2297341 A4 EP2297341 A4 EP 2297341A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- huntington
- disease
- compositions
- treatment
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71465208P | 2008-05-09 | 2008-05-09 | |
PCT/CA2009/000645 WO2009135322A1 (en) | 2008-05-09 | 2009-05-08 | Methods and compositions for the treatment of huntington's disease |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2297341A1 EP2297341A1 (en) | 2011-03-23 |
EP2297341A4 true EP2297341A4 (en) | 2013-01-09 |
Family
ID=41264389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09741640A Withdrawn EP2297341A4 (en) | 2008-05-09 | 2009-05-08 | Methods and compositions for the treatment of huntington's disease |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2297341A4 (en) |
AU (1) | AU2009244013B2 (en) |
CA (1) | CA2726866A1 (en) |
WO (1) | WO2009135322A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008317566B2 (en) | 2007-10-26 | 2014-05-01 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
SG171914A1 (en) | 2008-12-02 | 2011-07-28 | Chiralgen Ltd | Method for the synthesis of phosphorus atom modified nucleic acids |
AU2010270714B2 (en) | 2009-07-06 | 2015-08-13 | Wave Life Sciences Ltd. | Novel nucleic acid prodrugs and methods use thereof |
US9006198B2 (en) | 2010-02-08 | 2015-04-14 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
WO2011097643A1 (en) * | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
DK2734208T3 (en) | 2011-07-19 | 2017-06-19 | Wave Life Sciences Ltd | PROCEDURES FOR SYNTHESIS OF FUNCTIONALIZED NUCLEIC ACIDS |
US20140303235A1 (en) | 2011-08-11 | 2014-10-09 | Isis Pharmaceuticals, Inc. | Linkage modified gapped oligomeric compounds and uses thereof |
US9598458B2 (en) | 2012-07-13 | 2017-03-21 | Wave Life Sciences Japan, Inc. | Asymmetric auxiliary group |
SG11201500232UA (en) | 2012-07-13 | 2015-04-29 | Wave Life Sciences Pte Ltd | Chiral control |
JP6246121B2 (en) | 2012-07-13 | 2017-12-13 | 株式会社新日本科学 | Chiral nucleic acid adjuvant |
EP4086347A3 (en) | 2012-10-12 | 2023-01-11 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
EP3778618A1 (en) | 2013-02-04 | 2021-02-17 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
EP3095460A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
JPWO2015108047A1 (en) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant having immunity induction activity and immunity induction activator |
JPWO2015108048A1 (en) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | Chiral nucleic acid adjuvant and antitumor agent having antitumor activity |
US10160969B2 (en) | 2014-01-16 | 2018-12-25 | Wave Life Sciences Ltd. | Chiral design |
US10221416B2 (en) | 2014-04-24 | 2019-03-05 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising alpha-beta-constrained nucleic acid |
MA43072A (en) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
MA45270A (en) | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
EP4069846A1 (en) * | 2019-12-07 | 2022-10-12 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of htt |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020187931A1 (en) * | 2000-04-13 | 2002-12-12 | Michael Hayden | Modulating cell survival by modulating huntingtin function |
US20100299768A1 (en) * | 2007-06-18 | 2010-11-25 | Commissariat A L'energie Atomique | Reversible siRNA-Based Silencing of Mutant and Endogenous Wild-Type Huntingtin Gene and its Application for the Treatment of Huntington's Disease |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008005562A2 (en) * | 2006-07-07 | 2008-01-10 | University Of Massachusetts | Rna silencing compositions and methods for the treatment of huntington's disease |
EP2062980B1 (en) * | 2005-06-28 | 2011-08-31 | Medtronic, Inc. | Methods and sequences to preferentially suppress expression of mutated huntingtin gene. |
US9273356B2 (en) * | 2006-05-24 | 2016-03-01 | Medtronic, Inc. | Methods and kits for linking polymorphic sequences to expanded repeat mutations |
-
2009
- 2009-05-08 CA CA2726866A patent/CA2726866A1/en not_active Abandoned
- 2009-05-08 WO PCT/CA2009/000645 patent/WO2009135322A1/en active Application Filing
- 2009-05-08 AU AU2009244013A patent/AU2009244013B2/en not_active Ceased
- 2009-05-08 EP EP09741640A patent/EP2297341A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020187931A1 (en) * | 2000-04-13 | 2002-12-12 | Michael Hayden | Modulating cell survival by modulating huntingtin function |
US20100299768A1 (en) * | 2007-06-18 | 2010-11-25 | Commissariat A L'energie Atomique | Reversible siRNA-Based Silencing of Mutant and Endogenous Wild-Type Huntingtin Gene and its Application for the Treatment of Huntington's Disease |
Non-Patent Citations (2)
Title |
---|
DENOVAN-WRIGHT E M ET AL: "RNAi: a potential therapy for the dominantly inherited nucleotide repeat diseases", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 13, no. 6, 1 March 2006 (2006-03-01), pages 525 - 531, XP002452333, ISSN: 0969-7128 * |
See also references of WO2009135322A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2009135322A1 (en) | 2009-11-12 |
AU2009244013B2 (en) | 2015-06-25 |
EP2297341A1 (en) | 2011-03-23 |
AU2009244013A1 (en) | 2009-11-12 |
CA2726866A1 (en) | 2009-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2297341A4 (en) | Methods and compositions for the treatment of huntington's disease | |
HK1225970A1 (en) | Treatment of huntington's disease using laquinimod | |
IL246293B (en) | Novel compositions and methods for the treatment of immune related diseases | |
HK1212598A1 (en) | Composition and method for the prevention of oral disease | |
EP2212440A4 (en) | Methods and compositions for the diagnosis and treatment of esphageal adenocarcinomas | |
GB2443287B (en) | Methods, compositions and formulations for the treatment of thyroid eye disease | |
EP2120580A4 (en) | Compositions and methods for the treatment of metabolic disorders | |
EP2125855A4 (en) | Methods and compositions for the treatment of cancer or other diseases | |
EP2152318A4 (en) | Uses and compositions for treatment of psoriasis and crohn's disease | |
GB201108374D0 (en) | Compositions and methods for the treatment of altered synuclein function | |
EP2046993A4 (en) | Rna silencing compositions and methods for the treatment of huntington's disease | |
HK1145141A1 (en) | Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy | |
EP2217238A4 (en) | Methods and compositions for the treatment of proteinuric diseases | |
HK1245679A1 (en) | Methods and compositions for treating dermatological diseases and conditions | |
GB0718446D0 (en) | Compositions and methods for the treatment of infection | |
EP2271352A4 (en) | Compositions and methods for treatment of neoplastic disease | |
GB0909297D0 (en) | Composition for the treatment of skin conditions | |
EP2320939A4 (en) | Tissue kallikrein for the treatment of parkinson's disease | |
WO2010085799A9 (en) | Compositions and method for the treatment of parkinson's disease | |
IL217149A0 (en) | Compositions and methods for treating parkinson's disease | |
EP2421554A4 (en) | Tissue kallikrein for the treatment of huntington's disease | |
GB0620695D0 (en) | Composition and methods for the treatment of nurdegenerative disease | |
EP2142566A4 (en) | Methods and compositions for the treatment of proliferative diseases | |
PL2307380T3 (en) | N'-nitroxyalkylnicotinamides for the treatment of cardiovascular diseases | |
GB0808326D0 (en) | Compositions and methods for the treatment of fybromyalgia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20101209 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1154911 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20121211 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/14 20060101ALI20121205BHEP Ipc: A61K 31/713 20060101ALI20121205BHEP Ipc: C12Q 1/68 20060101AFI20121205BHEP Ipc: A61K 31/7088 20060101ALI20121205BHEP Ipc: C12N 15/85 20060101ALI20121205BHEP Ipc: G01N 33/53 20060101ALI20121205BHEP Ipc: C07H 21/00 20060101ALI20121205BHEP Ipc: C12N 15/63 20060101ALI20121205BHEP Ipc: C12N 15/11 20060101ALI20121205BHEP Ipc: G01N 33/68 20060101ALI20121205BHEP |
|
17Q | First examination report despatched |
Effective date: 20150511 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20170523 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1154911 Country of ref document: HK |